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1. Introduction {#sec005}
===============

The cohort study is the second level of evidence in evidence-based medicine. It has more accessible data sources and lower costs than randomized controlled trials, and the results are more in line with clinical practice \[[@pone.0232020.ref001]\]. Its range of application has developed from health-related influencing factors to assessing the effectiveness of medical control measures \[[@pone.0232020.ref002]\]. Since the mid-19th century, many classic cohort studies have been carried out internationally. For example, a multicenter AIDS cohort study conducted in 1984 concluded that even if patients were seropositive for human immunodeficiency virus type 1 \[HIV-1\], those without AIDS would not develop *Pneumocystis carinii* pneumonia unless their CD4+ cells were depleted to 200 or fewer per cubic millimeter \[[@pone.0232020.ref003]\]. Another study, using data from 31,546 people in 40 countries, found that high-quality diets can reduce the incidence of cardiovascular events in people over 55 years of age \[[@pone.0232020.ref004]\]. Therefore, cohort studies play an important role in the assessment of risk factors, outcomes, and preventive measures for disease occurrence.

Rheumatism is an ancient disease encompassing nearly 200 diseases in 10 categories. the discipline was founded later but grew faster than many others \[[@pone.0232020.ref005]\]. In recent years, its increasing incidence and prevalence have attracted the attention of researchers all over the world. Cohort studies based on etiology and pathology, to guide clinical treatment, have become commonly used in the field of rheumatology \[[@pone.0232020.ref006]--[@pone.0232020.ref008]\]. For example, the Framingham cohort study investigating risk factors for osteoarthritis (OA) showed no significant relationship between inflammatory markers and OA \[[@pone.0232020.ref009],[@pone.0232020.ref010]\]. In order to observe the risk of gout in people consuming fructose-rich beverages, 78,906 women were followed-up for 22 years, and the results showed that fructose-rich beverages increased the incidence of gout events \[[@pone.0232020.ref011]\]. China is a large country with many rheumatism patients, and some cohort studies have been carried out in recent years \[[@pone.0232020.ref012]\]. However, until now, their research status and quality have not been reviewed and evaluated.

This paper collects the literature on rheumatism cohort research conducted in China, discusses the progress of research in recent years, and evaluates the quality of research in the Chinese and English literature. The purpose of this study is to provide a reference for the improvement of future cohort studies.

2. Methods {#sec006}
==========

2.1 Search strategy {#sec007}
-------------------

The following databases were searched from their inception to January 2019. The English databases included PubMed, Web of Science, EMbase, and the Cochrane Library. The Chinese databases included the Chinese National Knowledge Infrastructure (CNKI), Wan Fang Database, the Chongqing Vip Information Database (VIP) and the Chinese Biomedical Database (SinoMed). For the English databases, the keyword searches used were "cohort studies", "rheumatic diseases", "autoimmune diseases" and "connective tissue diseases". The Medical Subject vocabulary (MeSH) searches used were "rheumatoid arthritis", "ankylosing spondylitis", "gout" and other common rheumatic diseases. For the Chinese-language searches, the same search strategy and search terms were used. The retrieval process is shown in [Fig 1](#pone.0232020.g001){ref-type="fig"}.

![Search and selection flow diagram.\
A total of 97 English articles and 526 Chinese articles were retrieved. After screening and exclusion, 19 English and 27 Chinese papers were included.](pone.0232020.g001){#pone.0232020.g001}

2.2 Study selection {#sec008}
-------------------

The documents retrieved were imported into the NoteExpress document management software to exclude duplicate literature. By reading the topic and abstracts of the literature, two researchers conducted a preliminary screening, and they subsequently read full text of each paper. Two researchers independently judged whether the inclusion criteria were met, and the divergences were referred to the third investigator for assistance.

2.3 Inclusion criteria {#sec009}
----------------------

Studies that met the following criteria were selected for further analysis: the study type was a cohort study; the study participants were patients with rheumatic diseases from China; the study provided complete research data; languages were limited to Chinese or English; and the study was published in an official journal.

2.4 Exclusion criteria {#sec010}
----------------------

Studies that met the following criteria were excluded: repeated published literature; reviews; systematic reviews; clinical control studies; randomized controlled trials; animal experiments; the full text remained unavailable after contacting the author.

2.5 Data extraction {#sec011}
-------------------

Two reviewers (H Zhang and GX Yi) screened all titles and abstracts of the studies independently. Full texts of potentially-included studies were retrieved for further identification, according to the above criteria. A data extraction form was created, including the author, the year of publication, journal name, case collection location, sample size, disease researched, etc ([Table 1](#pone.0232020.t001){ref-type="table"}). The disease was classified according to the *International Classification of Diseases (10th Edition)*. Disagreements were resolved by consultation with other authors, and a final decision was made through discussions and consultations.

10.1371/journal.pone.0232020.t001

###### List of basic characteristics of literature.

![](pone.0232020.t001){#pone.0232020.t001g}

  Study                                         Year of publication   Disease    Journal                                                        Case collection location   Sample size   Funding   Informed consent   Ethical review
  --------------------------------------------- --------------------- ---------- -------------------------------------------------------------- -------------------------- ------------- --------- ------------------ -------------------------------------------
  Adab P et al \[[@pone.0232020.ref013]\]       2014                  RA         Rheumatology (Oxford)                                          Guangzhou                  7349                                       N/A[^a^](#t001fn001){ref-type="table-fn"}
  Liu Q et al \[[@pone.0232020.ref014]\]        2015                  OA         Osteoarthritis Cartilage                                       Wuchuan                    1026          N/A       N/A                N/A
  Ma L et al \[[@pone.0232020.ref015]\]         2018                  Gout       Clinical rheumatology                                          Qingdao                    5693          N/A                          
  Wang Y et al \[[@pone.0232020.ref016]\]       2013                  Gout       Rheumatology international                                     Shandong Province          659           N/A                          
  Wu J et al \[[@pone.0232020.ref017]\]         2018                  SLE        BMJ open                                                       Shanghai                   1352          N/A                          
  Wang Z et al \[[@pone.0232020.ref018]\]       2018                  SLE        Lupus                                                          Beijing                    260           N/A                          
  Yuan S et al \[[@pone.0232020.ref019]\]       2013                  SLE        The Journal of rheumatology                                    Guangzhou                  3823                    N/A                N/A
  Zou YF et al \[[@pone.0232020.ref020]\]       2013                  SLE        Inflammation                                                   Hefei City                 260                                        
  Lin H et al \[[@pone.0232020.ref021]\]        2012                  SLE        Clinical rheumatology                                          Chengdu                    158           N/A                          
  Xu W et al \[[@pone.0232020.ref022]\]         2016                  Myositis   Immunology letters                                             Zaozhuang                  32380         N/A       N/A                
  Peng JM et al \[[@pone.0232020.ref023]\]      2016                  Myositis   PloS one                                                       Beijing                    109           N/A       N/A                N/A
  Chen D et al \[[@pone.0232020.ref024]\]       2014                  Myositis   Clinical and experimental rheumatology                         Guangzhou                  253           N/A                          N/A
  Tian Y et al \[[@pone.0232020.ref025]\]       2015                  OP         Osteoporos Int                                                 Wuhan                      38295                                      
  Liu H et al \[[@pone.0232020.ref026]\]        2018                  KBD        Biological trace element research                              Shanxi Province            1214                                       
  Fan X et al \[[@pone.0232020.ref027]\]        2017                  PBC        Scientific reports                                             Chengdu                    769           N/A                          
  Yang C et al \[[@pone.0232020.ref028]\]       2017                  HUA        PLoS One                                                       Luzhou                     4668          N/A                          
  Cui L et al \[[@pone.0232020.ref029]\]        2017                  HUA        Mod Rheumatol                                                  Tangshan                   101510        N/A                          
  Cao J et al \[[@pone.0232020.ref030]\]        2017                  HUA        Int J Environ Res Public Health                                Shandong Province          58542                                      
  Villegas R et al \[[@pone.0232020.ref031]\]   2010                  HUA        Metab Syndr Relat Disord                                       Shanghai                   3978                                       
  Wen J et al \[[@pone.0232020.ref032]\]        2018                  OA         Chinese Journal of Clinical Healthcare                         Anhui Province             1904                    N/A                N/A
  Fang Y et al \[[@pone.0232020.ref033]\]       2018                  RA         Chinese Journal of Clinical Healthcare                         Hefei                      1812                                       N/A
  Zhao M et al \[[@pone.0232020.ref034]\]       2016                  HUA        Hainan Medical Journal                                         Beijing                    126           N/A       N/A                N/A
  Zhang Y et al \[[@pone.0232020.ref035]\]      2015                  AS         BMJ Chinese Edition                                            Shan Tou                   830           N/A                          
  Ji XJ et al \[[@pone.0232020.ref036]\]        2016                  AS         Chinese Journal of Rheumatology                                Beijing                    449           N/A       N/A                N/A
  Zhou W et al \[[@pone.0232020.ref037]\]       2018                  HUA        Chinese Journal of Health Management                           Changsha                   1859                                       
  Zhang CY et al \[[@pone.0232020.ref038]\]     2014                  HUA        China Preventive Medicine                                      Beijing                    811           N/A       N/A                N/A
  Jiang W et al \[[@pone.0232020.ref039]\]      2018                  Myositis   Chinese Journal of Rheumatology                                Beijing                    480                     N/A                N/A
  Wen J et al \[[@pone.0232020.ref040]\]        2018                  AS         World Journal of Integrated Traditional and Western Medicine   Hefei                      399                     N/A                N/A
  Cao J et al \[[@pone.0232020.ref041]\]        2017                  HUA        Journal of Shandong University (Health Science)                Shandong Province          26006                   N/A                N/A
  Shou F et al \[[@pone.0232020.ref042]\]       2010                  HUA        Prevention and Treatment of Cardio Cerebral Vascular Disease   Zhejiang Province          374           N/A       N/A                N/A
  Li Y et al \[[@pone.0232020.ref043]\]         2008                  HUA        CHINESE JOURNAL OF INTERNAL MEDICINE                           Beijing                    1442                    N/A                N/A
  Gu X et al \[[@pone.0232020.ref044]\]         2016                  OA         Chinese Journal of Joint Surgery (Electronic Version)          Shanghai                   362           N/A       N/A                N/A
  Zhang W et al \[[@pone.0232020.ref045]\]      2002                  SLE        CHINESE JOURNAL OF RHEUMATOLOGY                                Shanghai                   71            N/A       N/A                N/A
  Li D et al \[[@pone.0232020.ref046]\]         2017                  OP         Chinese Journal of Osteoporosis                                Zhongshan                  96                      N/A                N/A
  Li J et al \[[@pone.0232020.ref047]\]         2016                  RA         CHINA HEALTH INSURANCE                                         Zhuzhou                    49            N/A                          N/A
  Mu X et al \[[@pone.0232020.ref048]\]         2010                  RA         HEBEI MEDICAL JOURNAL                                          Beijing                    58            N/A       N/A                N/A
  Zhou Y et al \[[@pone.0232020.ref049]\]       2016                  SLE        Journal of Applied Clinical Pediatrics                         Shanghai                   60                                         
  Yang YF et al \[[@pone.0232020.ref050]\]      2009                  SLE        MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN NORTH CHINA    Taiyuan                    79            N/A       N/A                N/A
  Zhang C \[[@pone.0232020.ref051]\]            2017                  HUA        World Journal of Complex Medicine                              Zoucheng                   230           N/A       N/A                N/A
  Wu Y et al \[[@pone.0232020.ref052]\]         2017                  HUA        Chinese Journal of Gerontology                                 Suzhou                     1628          N/A                          N/A
  Zha Z \[[@pone.0232020.ref053]\]              2015                  HUA        Medical Information                                            Suzhou                     937           N/A       N/A                N/A
  Yang Y et al \[[@pone.0232020.ref054]\]       2014                  HUA        Chinese Journal of Difficult and Complicated Cases             Wuhan                      266           N/A       N/A                N/A
  Lao Y \[[@pone.0232020.ref055]\]              2015                  HUA        Chinese Primary Health Care                                    Suzhou                     994           N/A       N/A                N/A
  Liu X et al \[[@pone.0232020.ref056]\]        2014                  HUA        Chinese Journal of Diabetes                                    Tangshan                   8603          N/A                          N/A
  Yuan YD et al \[[@pone.0232020.ref057]\]      2017                  KD         Chinese Journal of Contemporary Pediatrics                     Xuzhou                     404           N/A       N/A                N/A
  Ji XJ et al \[[@pone.0232020.ref058]\]        2018                  AS         Chinese Journal of Internal Medicine.                          Beijing                    897                                        

^a^N/A: Not Applicable. RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus; OP: Osteoporosis; KBD: Kashin-Beck disease; PBC: Primary biliary cirrhosis; HUA: Hyperuricemia; OA: Osteoarthritis; AS: Ankylosing spondylitis; KD: Kawasaki disease.

2.6 Assessment of method quality {#sec012}
--------------------------------

The study quality was evaluated according to the Newcastle--Ottawa Scale (NOS). The NOS is divided into selection (4 points), comparability (2 points) and outcome (3 points). There were eight items in three columns, and the final score was 0--9 points. The higher the score, the higher the quality. 0--4 points indicated low quality, and 5--9 points indicated high quality. Supplementary items for evaluation of methodological quality were as follows: design type of the study, calculation of sample size, informed consent and ethical review, statistical analysis methods, etc.

2.7 Statistical analysis {#sec013}
------------------------

Statistical analysis was performed using SPSS version 23.0 (IBM Corp., Armonk, NY, USA). Data were presented as mean and standard deviation or frequency and percentage. Comparisons were conducted between the two groups. For normally distributed variables, means were compared using the *t-*test and nonparametric variables were analyzed using Pearson's chi-squared test. Two-tailed *P* values were used, with a *P* \< 0.05 considered statistically significant.

3. Results {#sec014}
==========

3.1 Search results {#sec015}
------------------

A total of 573 studies were retrieved. According to the aforementioned screening criteria and double assessment by two reviewers, we excluded 151 duplicate documents by reading topics and abstracts, removed 330 documents that did not meet the inclusion criteria, ruled out 46 non-conforming documents by reading the full text, and finally incorporated 46 articles, including 19 English articles \[[@pone.0232020.ref013]--[@pone.0232020.ref031]\] and 27 Chinese articles \[[@pone.0232020.ref032]--[@pone.0232020.ref058]\]. The specific search process is illustrated in [Fig 1](#pone.0232020.g001){ref-type="fig"}.

3.2 Basic characteristics of the literature {#sec016}
-------------------------------------------

### 3.2.1 Disease classification {#sec017}

A total of 11 diseases were included in the 46 articles, and hyperuricemia (16 articles) was the most studied, followed by systemic lupus erythematosus (8 articles). The specific disease distribution is shown in [Fig 2](#pone.0232020.g002){ref-type="fig"}.

![Distribution of disease types.\
Rheumatic disease cohort studies involve 11 disease types. The abscissa represents the quantity; the ordinate represents the disease type.](pone.0232020.g002){#pone.0232020.g002}

### *3*.*2*.2 Year of publication {#sec018}

The earliest research reports were published in 2002, and 36 studies have been reported in the last four years. The distribution of specific publication years is shown in [Fig 3A](#pone.0232020.g003){ref-type="fig"}.

![Publication year and distribution of sample size.\
**3a.** Publication year of Cohort study literature on rheumatic diseases. The abscissa represents the year; the ordinate represents the quantity. **3b.** Distribution of sample size. The abscissa represents the number of samples; the ordinate represents the number of studies.](pone.0232020.g003){#pone.0232020.g003}

### 3.2.3 Study types {#sec019}

Sixteen prospective cohort studies were found \[[@pone.0232020.ref014],[@pone.0232020.ref020],[@pone.0232020.ref026],[@pone.0232020.ref029],[@pone.0232020.ref030],[@pone.0232020.ref036],[@pone.0232020.ref042],[@pone.0232020.ref045]--[@pone.0232020.ref047],[@pone.0232020.ref051]--[@pone.0232020.ref056]\], which included 11 studies in Chinese and five studies in English. Moreover, 15 retrospective cohort studies were found \[[@pone.0232020.ref015],[@pone.0232020.ref017]--[@pone.0232020.ref019],[@pone.0232020.ref021]--[@pone.0232020.ref024],[@pone.0232020.ref027],[@pone.0232020.ref028],[@pone.0232020.ref032],[@pone.0232020.ref035],[@pone.0232020.ref044],[@pone.0232020.ref050],[@pone.0232020.ref057]\], including 10 in English and five in Chinese. In addition, 14 papers did not describe the type of study and could not be judged \[[@pone.0232020.ref013],[@pone.0232020.ref016],[@pone.0232020.ref025],[@pone.0232020.ref031],[@pone.0232020.ref033],[@pone.0232020.ref034],[@pone.0232020.ref037]--[@pone.0232020.ref041],[@pone.0232020.ref043],[@pone.0232020.ref048],[@pone.0232020.ref058]\], and there was only one ambispective cohort study \[[@pone.0232020.ref049]\]. The distribution of specific research types is shown in [Table 2](#pone.0232020.t002){ref-type="table"}. It is worth noting that sample size calculation was mentioned in only one literature \[[@pone.0232020.ref040]\].

10.1371/journal.pone.0232020.t002

###### The distribution of literature types in the cohort studies.

![](pone.0232020.t002){#pone.0232020.t002g}

  Study Types                                                           English   Chinese        
  --------------------------------------------------------------------- --------- --------- ---- --------
  **Prospective cohort study**                                          5         26.32     11   40.74
  **Retrospective cohort study**                                        10        52.63     5    18.52
  **Ambispective cohort study**[^a^](#t002fn001){ref-type="table-fn"}   0         0.00      1    3.70
  **Could not be judged**[^b^](#t002fn002){ref-type="table-fn"}         4         21.05     10   37.04
  **Total**                                                             19        100.00    27   100.00

^a^Based on a retrospective cohort study, prospective observations continue for a period of time, which is a model that combines prospective cohort studies with retrospective cohort studies.

^b^The researches did not state the study type clearly and that could not be judged from the study.

### 3.2.4 Sample size {#sec020}

A total of 313,564 subjects were included in the 46 studies, with a minimum of 49 cases and a maximum of 26,006 cases in Chinese, a minimum of 109 cases and a maximum of 101,510 cases in English. The sample size was less than 500 cases in 26.32% and 55.56% of English and Chinese studies, respectively. This difference was statistically significant (P\< 0.05), and the specific sample size distribution is shown in [Fig 3B](#pone.0232020.g003){ref-type="fig"}.

### 3.2.5 Informed consent and ethical review {#sec021}

The informed consent and ethical review data are shown in [Table 1](#pone.0232020.t001){ref-type="table"}. Informed consent reached 78.95% in English, but only 29.63% in Chinese. The difference between the two groups was obvious (P\< 0.01). A total of 84.21% of English literature studies conducted ethical reviews, while only 14.81% conducted such reviews in the Chinese literature. As a result, statistically significant differences were found (P\< 0.01).

### 3.2.6 Statistical methods {#sec022}

In this study, 73.68% of English studies and 55.56% of Chinese studies analyzed the baseline data, and only one reported data loss \[[@pone.0232020.ref035]\]. Three English and nine Chinese studies used only single-factor statistical analysis methods, such as single-factor variance analysis, t-tests, χ^2^ test, non-parametric testing, etc. One Chinese and one English study used Cox regression analyses to analyze effects over time; 15 English and 17 Chinese studies used logistic regression and Cox regression analysis to correct for the effects of confounding factors. The distribution of statistical analysis methods in Chinese and English studies is shown in [Fig 4](#pone.0232020.g004){ref-type="fig"}.

![Analysis methods.\
**4a.** Statistical analysis methods in English literature. **4b.** Statistical analysis methods in Chinese literature.](pone.0232020.g004){#pone.0232020.g004}

3.3 NOS methodological quality evaluation {#sec023}
-----------------------------------------

The NOS \[[@pone.0232020.ref059]\] was used to evaluate the 46 articles included in the study. First, both Chinese and English studies had low scores for the "representativeness of the exposed cohort". Most of the studies were based on a specific group of people, such as a group of retired employees, medical examination staff of a company, and so on. Second, the English papers scored worse than the Chinese papers on the "comparability between groups" entries, because they did not control for important factors and confounding factors that could affect the results. Finally, the follow-up was described in only 13 English articles and eight Chinese articles. The Chinese literature scored lower than the English literature for follow-up time, and the follow-up time was generally insufficient. The scores for the "sufficient follow-up" entries in both groups were low. The specific evaluation scores are shown in [Table 3](#pone.0232020.t003){ref-type="table"}.

10.1371/journal.pone.0232020.t003

###### Quality assessment of cohort studies using the Newcastle--Ottawa Scale.

![](pone.0232020.t003){#pone.0232020.t003g}

  Items                                                                      English   Chinese   χ^2^   *P*              
  -------------------------------------------------------------------------- --------- --------- ------ ------- -------- ---------------------------------------------
  **Selection**                                                                                                          
  1\) Representativeness of the exposed group                                6         31.58     7      25.93   0.176    0.675
  Selection of the non exposed cohort                                        19        100       26     96.3    11.409   0.001[^a^](#t003fn001){ref-type="table-fn"}
  Ascertainment of exposure                                                  16        84.21     23     85.19   0        1.000
  Demonstration that outcome of interest was not present at start of study   7         36.84     12     44.44   0.266    0.606
  **Comparability**                                                                                                      
  Comparability of cohorts on the basis of the design or analysis                                                        
  a\) Study controls for the most important factor                           12        63.16     25     92.59   4.412    0.036[^a^](#t003fn001){ref-type="table-fn"}
  b\) Study controls for any additional factor                               12        63.16     21     77.78   1.176    0.278
  **Outcome**                                                                                                            
  1\) Assessment of outcome                                                  14        73.68     25     92.59   1.799    0.180
  Was follow-up long enough for outcomes to occur                            13        68.42     8      29.63   6.764    0.009[^a^](#t003fn001){ref-type="table-fn"}
  Adequacy of follow up of cohorts                                           7         36.84     9      33.33   0.061    0.805

^a^It represents statistical significance (*P*\< 0.05)

According to the NOS evaluation criteria, the average score for the English literature was 5.59 ± 1.25, and the average score for the Chinese literature was 6.06 ± 1.11. The quality of the two groups was good, and the scores were mainly concentrated between 4--7. The average score of Chinese studies was higher than that of English studies. The difference between the groups was significant (*P*\< 0.01). [Table 4](#pone.0232020.t004){ref-type="table"} gives the specific scores.

10.1371/journal.pone.0232020.t004

###### The scores of cohort studies on the Newcastle--Ottawa items.

![](pone.0232020.t004){#pone.0232020.t004g}

  NOS   English   Chinese       
  ----- --------- --------- --- -------
  3     1         5.26      0   0.00
  4     2         10.53     6   22.22
  5     7         36.84     5   18.52
  6     4         21.05     6   22.22
  7     4         21.05     9   33.33
  8     1         5.26      1   3.70

4. Discussion {#sec024}
=============

An international cohort study on rheumatism is ongoing, and many large-sample multi-center clinical studies have been carried out. For example, the Framingham cohort study in the United States on the risk factors for osteoarthritis found that meniscal injury in the middle-aged and elderly populations increased with age and had no parallel relationship with clinical symptoms \[[@pone.0232020.ref060]\]. A retrospective cohort of 37,338 twins across Denmark showed that genes play only a minor role in the pathogenesis of rheumatoid arthritis \[[@pone.0232020.ref061]\]. Scholars at the University of St. Petersburg in Russia followed 498 women with systemic lupus erythematosus for 14 years. The research results suggested that early death was most common in those with active lupus or concurrent infections, and late death was more common in patients with atherosclerotic coronary heart disease or acute myocardial infarction \[[@pone.0232020.ref062]\]. It is clear that cohort studies have played an important role in the prevention and treatment of rheumatism.

According to the analysis of the basic characteristics of the 46 studies evaluated herein, a total of 11 diseases were studied in all cohort studies. In the past four years, 78.26% the literature has been published, indicating that cohort research on rheumatism in China developed late, and the degree of emphasis has risen in recent years. Most reports described retrospective cohort studies, and 14 reports did not allow us to judge the type of research. Only one bidirectional cohort study was published, which may be related to its difficulty in implementation and high cost. The average sample size of studies in the Chinese literature was smaller than that of those in the English literature. Six Chinese studies had fewer than 100 participants. With small sample sizes, studies show shortcomings of under representation \[[@pone.0232020.ref063],[@pone.0232020.ref064]\], leading to a low generalizability of Chinese cohort research. As can be learned from the statistical results, the large-scale Chinese reports with more than 500 cases accounted for 44.44%, while this percentage was 73.68% in the English reports. Of the 46 studies, only one reported an estimate of the sample size. With regard to informed consent and ethical review, the English literature was significantly better than the Chinese literature. However, 26.32% of English reports and 44.44% of Chinese reports did not describe baseline characteristics, which will affect the interpretation of the results \[[@pone.0232020.ref065]\].Nine of the Chinese studies used only univariate analyses to compare differences between groups, and because there are no other factors controlled, this may result in bias in the results. In summary, the Chinese rheumatism cohort study developed late, involves fewer disease types, shorter follow-up time, and lack of multi-center large sample studies, which limit the theoretical and applied value of rheumatism cohort research in China. Therefore, it is particularly important to improve the quantity and quality of rheumatism cohort studies \[[@pone.0232020.ref066]\].

The NOS scale is a commonly used method for the evaluation of cohort studies \[[@pone.0232020.ref067]\]. In this paper, the 46 documents retrieved were evaluated using the NOS. First, the results show that the Chinese score was higher than the English score, although the overall scores were mainly between 4 and 7 points. This may have been related to the exclusion of non-standardized and low-quality papers during the process of selecting the literature, resulting in a higher overall score. Second, both the Chinese and English literature scored higher on items such as "selection of the non-exposed cohort", "ascertainment of exposure", and "assessment of outcome", but the score for "representation of the exposed group" was lower. The main reason for this is that the exposed group was generally a specific group, such as outpatients, inpatients or a group of employees, and cannot represent the entire population. In addition, both Chinese and English studies scored lower on "demonstration that outcome of interest was not present at start of study", because the paper did not explicitly explain or did not mention the relevant information. Third, 17 Chinese and nine English reports did not describe follow-up, and did not score on the item "whether the group was adequately followed". Finally, the Chinese studies were inferior to the English studies on "was follow-up long enough for outcomes to occur", because the Chinese studies did not specify or anticipate the required follow-up time and we were unable to determine whether the follow-up time was sufficient. However, Chinese studies scored better than English studies on the "select the most important factor" entry. The Chinese studies not only controlled important factors such as time, but also controlled other confounding factors such as age, gender, and duration of disease. Obviously, both the Chinese and English reports have different advantages and disadvantages, and it is necessary that researchers should learn from each other.

Although rheumatism cohort studies in China have shown a great deal of progress, there are still many areas that need improvement. For instance, researchers should try to avoid the choice of specific populations for exposure groups. Attention should be paid as to "Demonstration that outcome of interest was not present at start of study", so as not to affect the observation of the results. In addition, the follow-up time should be based on the time of occurrence of the observations, to estimate a sufficiently long follow-up time, and the follow-up process should be standardized and detailed. In addition, we should also pay attention to more rheumatic diseases that have not been studied, conduct multi-center large sample cohort studies as much as possible, improve informed consent and ethical review, and select appropriate statistical methods. The above methods can provide information for future rheumatism cohort studies and improve the standardization and quality of cohort research in China.

5. Conclusion {#sec025}
=============

In this paper, we reviewed the progress and evaluated the quality of cohort studies on rheumatic diseases in China. On the one hand, the results showed that the Chinese rheumatic disease cohort studies developed late, with small sample sizes and fewer types of rheumatism. On the other hand, NOS quality assessment results show that the quality of Chinese reports is better than English reports. Some shortcomings were also discovered. In particular, "selecting exposed groups", "controlling the outcomes before study implementation" and "following up groups" need to be improved. Therefore, well-designed multicenter and large-scale cohort studies are needed to improve clinical studies of rheumatic diseases in China.

Supporting information {#sec026}
======================
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2\. During our internal evaluation of your manuscript, we noticed several typos. For instances, line 37: Englishstudies, line 38: selectionofstatistical, line 176:Table 2.t. Please note that PLOS ONE does not copyedit accepted manuscripts, so please ensure the language in submitted articles is clear, correct, and unambiguous.
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Emendations: We have corrected them one by one.

line 27: the statement of "andanalyzed" was corrected as "and analyzed";

line 34: the statement of "Englishstudies" was corrected as "English studies";

line 35: the statement of "selectionofstatistical" was corrected as "selection of statistical";

line 60: the statement of "pneumoniaunless" was corrected as "pneumonia unless";

line 162: the statement of "Table 2.t" was corrected as "Table 2. It";

line 234: the statement of "underrepresentation" was corrected as "under representation".

line 240: the statement of "literature.However" was corrected as "literature. However".

line 245: the statement of "developedlate" was corrected as "developed late".

line 253: the statement of "points.This" was corrected as "points. This".

line 254: the statement of "papersduring" was corrected as "papers during".

3\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-> information.

Response: All data and information have been presented in the manuscript, without additional information to supplement.

4\. Please confirm that you have included all items recommended in the PRISMA checklist including identifying the study as a meta-analysis or systematic review in the title.

Response: We confirmed that we have included all items recommended in the PRISMA checklist and add "a systematic review" in the title.

5\. The manuscript needs English editing by a native English speaker to improve the quality of language.

Response: Ok! To improve English expression, we invited International Science Editing to polish and edit this paper.

Emendations: The corrections in the paper are as following:

We have rewritten this part according to the requirements of the magazine. The comment symbol for the author\'s name was changed and Current Address was added. In addition, the information format of corresponding author has been changed.

We have fixed the font format for headings at all levels.

We upload our figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool to ensure that figures meet PLOS requirements. Besides, the titles, legends, comment marks of the pictures and tables were changed as required.

All references are supplemented as much as possible with doi and PMID, and Article 59 references have been updated.

We corrected three sentences.

Line 46: the sentence "The quality of the research was generally similar, and all reports were insufficient, in both the English and Chinese literature." was corrected as "The quality of Chinese studies was better than English studies, and all reports were insufficient."

Line 213: the sentence "A retrospective cohort of 37,338 twins across Denmark showed that genes play only a minor role in the pathogenesis of rheumatoid arthritis" was corrected as "the Framingham cohort study in the United States on the risk factors for osteoarthritis found that meniscal injury in the middle-aged and elderly populations increased with age and had no parallel relationship with clinical symptoms."

Line 291: the sentence "On the other hand, the results of the NOS quality evaluation suggest that the quality of the study is similar in Chinese and English reports." was corrected as "On the other hand, NOS quality assessment results show that the quality of Chinese reports is better than English reports."

Some changes that do not affect the meaning of the content are not listed, but they are marked in red in the article.
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